The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | iStopMM study – the impact of nationwide screening
Sigurdur Kristinsson, MD, PhD, University of Iceland, Reykjavík, Iceland, shares some insights into the iStopMM study (NCT03327597), which is looking at early detection, and therefore early intervention in patients with smoldering multiple myeloma (SMM). The study aims to minimize the incidence of myeloma in Iceland with the hope of treating patients to prevent them from developing myeloma in the future. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Disclosures
Gelgene, Amgen
